Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

  • ID: 4576038
  • Report
  • Region: Asia Pacific
  • 125 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AbbVie
  • Biocon
  • Eli Lilly
  • Kyowa Hakko Kirin
  • Novartis
  • UCB
  • MORE

Psoriasis is a chronic, autoimmune, relapsing, inflammatory disease triggered by deregulated thymus-derived cells (T cells), resulting in inflammation and benign hyperplasia of keratinocytes within the skin affecting around 2-3% of the world’s population. Manifestations of affected skin are red thickened plaques with an overlying silver-white scale, which significantly impairs the patient’s physical and mental wellbeing.

The Asia-Pacific (APAC) psoriasis market is forecast to grow from $933.1m in 2017 to $1,997.3m in 2024, at a compound annual growth rate (CAGR) of 11.5%. Over the forecast period the prevalence of psoriasis is expected to increase significantly across the APAC markets, mainly due to alterations in environmental and lifestyle risk factors.

While psoriasis is likely caused by a genetic predisposition, other intrinsic and environmental factors, including those linked to lifestyle, play a role in the development and progression of disease, including smoking, alcohol consumption, and obesity. The rising prevalence, together with an increase in the diagnosis rate, heightened awareness and rising demand for improved healthcare infrastructure are expected to contribute to market growth.

The treatment landscape of psoriasis is dense and complex, with treatment options prescribed based on the severity of the indication. More than 80% of psoriasis patients fall under the category of mild or moderate, whose first line of treatment is topical drugs or phototherapy, or a combination of both. For severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as the first line. However, toxicity concerns mean that they cannot be prescribed for long durations.

Biologics have emerged as highly potent treatment options in patients for whom traditional systemic therapies fail to achieve an adequate response, or are not tolerated owing to adverse effects, or are unsuitable owing to comorbidities. New molecules are continually being added to this group. TNF-a inhibitor were the first class of biologics approved for the treatment of psoriasis and has long dominated the therapeutic space. However, the dominance of TNF-a inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab will be challenged during the forecast period by the highly effective IL-17 and IL-23 inhibitor therapies.

The key research inclusions of the report "Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market" are:

  • Key reasons driving the psoriasis market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.
  • Introduction to psoriasis, detailing the epidemiology, symptoms, etiology, pathophysiology, and diagnosis for patients.
  • Comprehensive Heatmap and detailed analysis of the drugs currently marketed for psoriasis.
  • Analysis of the pipeline for psoriasis, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Assessment of promising late-stage pipeline molecules in terms of their potential competitive strength.
  • Forecasts for the psoriasis market, including epidemiology, treatment usage patterns, pricing and market size for the 2017-2024 period.
  • Key market drivers and barriers for the psoriasis market.
  • Major deals that have taken place in the global psoriasis market.

Scope

  • The Asia-Pacific psoriasis market will be valued at $1,997.3m in 2024, growing from $933.1m in 2017, at a compound annual growth rate (CAGR) of 11.5%.
  • What are the key factors driving the Asia-Pacific psoriasis treatment market?
  • How will novel IL-23 inhibitor therapy Tremfya, which holds first-to-market advantage, contribute to growth?
  • What will be the impact of the new IL-17 and IL-23 inhibitor therapies?
  • How will branded therapies be affected by upcoming pipeline therapies?
  • The psoriasis pipeline contains a range of molecule types and molecular targets, including those that are well established in psoriasis and novel target therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Is there potential for pipeline molecules to address unmet needs within the psoriasis market?
  • Late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • Which classes of drugs are most prominent in the pipeline?
  • How will the approval of risankizumab and tildrakizumab, which hold a key advantage in terms of dosing schedule over IL-23 competitor Tremfya, affect the competitive landscape?
  • Various drivers and barriers will influence the market over the forecast period.
  • What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?
  • What licensing and co-development deals have occurred within this therapy area since 2007?

Reasons to buy

  • Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
  • Visualize the composition of the psoriasis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the psoriasis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict psoriasis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the psoriasis deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • Biocon
  • Eli Lilly
  • Kyowa Hakko Kirin
  • Novartis
  • UCB
  • MORE

1 Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.3.1 Skin Manifestations
2.3.2 Psychological Impact
2.4 Etiology, Co-morbidities and Risk Factors
2.4.1 Genetics
2.4.2 Psoriatic Arthritis
2.4.3 Mental Health Disorders
2.4.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption
2.4.5 Infections
2.4.6 Koebner Phenomenon
2.4.7 Other Immune-Mediated Diseases
2.5 Pathophysiology
2.6 Diagnosis
2.7 Prognosis
2.8 Treatment and Management
2.8.1 Pharmacological Therapies
2.8.2 Non-pharmacological Therapies
2.8.3 Combination and Rotational Therapies
2.8.4 Quality of Life Assessments

3 Marketed Products
3.1 Overview
3.1.1 Tremfya (guselkumab) - Janssen Biotech
3.1.2 Cosentyx (secukinumab) - Novartis
3.1.3 Otezla (apremilast) - Celgene
3.1.4 Alzumab (Itolizumab) - Biocon
3.1.5 Diavobet (calcipotriene and betamethasone dipropionate) - LEO Pharma
3.1.6 Lumicef (brodalumab) - Kyowa Hakko Kirin
3.1.7 Taltz (ixekizumab) - Eli Lilly
3.1.8 Stelara (ustekinumab) - Janssen Biotech
3.1.9 Enbrel (Etanercept) - Amgen
3.1.10 Remicade (Infliximab) - Janssen Biotech
3.1.11 Humira (Adalimumab) - AbbVie
3.1.12 Methotrexate
3.1.13 Cyclosporine
3.1.14 Acitretin
3.2 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Tildrakizumab - Sun Pharma
4.4.2 Risankizumab - AbbVie
4.4.3 Tapinarof - Welichem Biotech
4.4.4 Bimekizumab - UCB
4.4.5 Certolizumab Pegol - UCB
4.5 Comparative Efficacy and Safety of Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Support and Assistance from the Healthcare Systems
7.1.2 Rising Prevalence
7.1.3 Potential for Innovative Pipeline Molecules to Address Significant Unmet Need
7.1.4 Increasing Acceptance of Biologics and Biosimilars
7.2 Barriers
7.2.1 Use of Phototherapy and Traditional Medicines
7.2.2 Low Compliance and Treatment Discontinuation
7.2.3 Regulatory Submissions and Clinical Trial Requirement
7.2.4 High Prices of Therapeutics to Slow Down Market Growth
7.2.5 Growing Competition to Hinder Uptake of Pipeline Drugs

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 IND/CTA-filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Market Forecasts to 2024
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis 

List of Tables
Table 1: Psoriasis Therapeutics Market, APAC, Types of Psoriasis
Table 2: Psoriasis Therapeutics Market, APAC, Age Distribution of Psoriasis Prevalence in South Korea
Table 3: Psoriasis Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2007-2017
Table 4: Psoriasis Therapeutics Market, Global, Co-development Deals, 2007-2017
Table 5: Psoriasis Therapeutics Market, Global, All Pipeline Products, Discovery, 2018
Table 6: Psoriasis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018
Table 7: Psoriasis Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018
Table 8: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase I, 2018
Table 9: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase II, 2018
Table 10: Psoriasis Therapeutics Market, Global, All Pipeline Products, Phase III, 2018
Table 11: Psoriasis Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2018
Table 12: Psoriasis Therapeutics Market, Asia-Pacific, Market Forecast, 2017-2024
Table 13: Psoriasis Therapeutics Market, India, Market Forecast, 2017-2024
Table 14: Psoriasis Therapeutics Market, China, Market Forecast, 2017-2024
Table 15: Psoriasis Therapeutics Market, Australia, Market Forecast, 2017-2024
Table 16: Psoriasis Therapeutics Market, South Korea, Market Forecast, 2017-2024
Table 17: Psoriasis Therapeutics Market, Japan, Market Forecast, 2017-2024

List of Figures
Figure 1: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
Figure 2: Pipeline for Psoriasis Therapeutics, Global, 2018
Figure 3: Pipeline for Psoriasis Therapeutics by Molecular Target, Global, 2018
Figure 4: Psoriasis Therapeutics Market, APAC, Tildrakizumab Forecast ($m), 2018-2024
Figure 5: Psoriasis Therapeutics Market, APAC, Risankizumab Forecast ($m), 2019-2024
Figure 6: Psoriasis Therapeutics Market, APAC, Bimekizumab Forecast ($m), 2022-2024
Figure 7: Psoriasis Therapeutics Market, APAC, Certolizumab Pegol Market ($m), 2021-2024
Figure 8: Psoriasis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
Figure 9: Psoriasis Therapeutics Market, Competitor Matrix for Psoriasis Marketed and Pipeline Products
Figure 10: Psoriasis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017
Figure 11: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017
Figure 12: Psoriasis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017
Figure 13: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017
Figure 14: Psoriasis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017
Figure 15: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017
Figure 16: Psoriasis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017
Figure 17: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017
Figure 18: Psoriasis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017
Figure 19: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 20: Psoriasis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 21: Psoriasis Therapeutics Market, Asia Pacific, Treatment Usage Patterns (‘000), 2017-2024
Figure 22: Psoriasis Therapeutics Market, Asia Pacific, Market Size ($m), 2017-2024
Figure 23: Psoriasis Therapeutics Market, India, Treatment Usage Patterns (’000), 2017-2024
Figure 24: Psoriasis Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024
Figure 25: Psoriasis Therapeutics Market, India, Market Size ($m), 2017-2024
Figure 26: Psoriasis Therapeutics Market, China, Treatment Usage Patterns (‘000), 2017-2024
Figure 27: Psoriasis Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024
Figure 28: Psoriasis Therapeutics Market, China, Market Size ($m), 2017-2024
Figure 29: Psoriasis Therapeutics Market, Australia, Treatment Usage Patterns (‘000), 2017-2024
Figure 30: Psoriasis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024
Figure 31: Psoriasis Therapeutics Market, Australia, Market Size ($m), 2017-2024
Figure 32: Psoriasis Therapeutics Market, South Korea, Treatment Usage Patterns (‘000), 2017-2024
Figure 33: Psoriasis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024
Figure 34: Psoriasis Therapeutics Market, South Korea, Market Size ($m), 2017-2024
Figure 35: Psoriasis Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2017-2024
Figure 36: Psoriasis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024
Figure 37: Psoriasis Therapeutics Market, Japan, Market Size ($m), 2017-2024
Figure 38: Psoriasis Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2017
Figure 39: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017
Figure 40: Psoriasis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017
Figure 41: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2017
Figure 42: Psoriasis Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2017
Figure 43: Psoriasis Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2017
Figure 44: Psoriasis Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2017
Figure 45: Psoriasis Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2017
Figure 46: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2017
Figure 47: Psoriasis Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie
  • Amgen
  • Biocon
  • Celgene
  • Eli Lilly
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Novartis
  • Sun Pharma
  • UCB
  • Welichem Biotech
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll